Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

NCT05201183 is registered in ClinicalTrials.gov with Naoyuki G. Saito, M.D., Ph.D. as lead sponsor.

NCT NCT05201183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Lead sponsor
Naoyuki G. Saito, M.D., Ph.D.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 31, 2023
Completion date
April 30, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes